Global Virus-like Particles (VLPs) Vaccine Market Growth 2026-2032
The global Virus-like Particles (VLPs) Vaccine market size is predicted to grow from US$ 655 million in 2025 to US$ 1164 million in 2032; it is expected to grow at a CAGR of 8.7% from 2026 to 2032.
VLP stands for virus-like particles. Virus-like particles are molecules that mimic viruses but are not infectious. They are a very effective way of creating vaccines against diseases such as human papillomavirus (HPV), hepatitis B, malaria, and more.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LP Information, Inc. (LPI) ' newest research report, the “Virus-like Particles (VLPs) Vaccine Industry Forecast” looks at past sales and reviews total world Virus-like Particles (VLPs) Vaccine sales in 2025, providing a comprehensive analysis by region and market sector of projected Virus-like Particles (VLPs) Vaccine sales for 2026 through 2032. With Virus-like Particles (VLPs) Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Virus-like Particles (VLPs) Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Virus-like Particles (VLPs) Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Virus-like Particles (VLPs) Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Virus-like Particles (VLPs) Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Virus-like Particles (VLPs) Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Virus-like Particles (VLPs) Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Virus-like Particles (VLPs) Vaccine market by product type, application, key manufacturers and key regions and countries.
VLP stands for virus-like particles. Virus-like particles are molecules that mimic viruses but are not infectious. They are a very effective way of creating vaccines against diseases such as human papillomavirus (HPV), hepatitis B, malaria, and more.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LP Information, Inc. (LPI) ' newest research report, the “Virus-like Particles (VLPs) Vaccine Industry Forecast” looks at past sales and reviews total world Virus-like Particles (VLPs) Vaccine sales in 2025, providing a comprehensive analysis by region and market sector of projected Virus-like Particles (VLPs) Vaccine sales for 2026 through 2032. With Virus-like Particles (VLPs) Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Virus-like Particles (VLPs) Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Virus-like Particles (VLPs) Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Virus-like Particles (VLPs) Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Virus-like Particles (VLPs) Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Virus-like Particles (VLPs) Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Virus-like Particles (VLPs) Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Virus-like Particles (VLPs) Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Live-Attenuated Vaccines
- Inactivated Vaccines
- Recombinant Vaccines
- Toxoid Vaccines
Segmentation by Application:
- Hepatitis
- HPV
- Others
This report also splits the market by region:
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Merck and Co.
- GlaxoSmithKline
- Pfizer
- Dynavax Technologies
- Sanofi
- Wantai BioPharm
- Serum Institute of India
- Bharat Biotech
- LG Chem
- VBI Vaccines
Key Questions Addressed in this Report
- What is the 10-year outlook for the global Virus-like Particles (VLPs) Vaccine market?
- What factors are driving Virus-like Particles (VLPs) Vaccine market growth, globally and by region?
- Which technologies are poised for the fastest growth by market and region?
- How do Virus-like Particles (VLPs) Vaccine market opportunities vary by end market size?
- How does Virus-like Particles (VLPs) Vaccine break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Virus-like Particles (VLPs) Vaccine Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Virus-like Particles (VLPs) Vaccine by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Virus-like Particles (VLPs) Vaccine by Country/Region, 2021, 2025 & 2032
2.2 Virus-like Particles (VLPs) Vaccine Segment by Type
2.2.1 Live-Attenuated Vaccines
2.2.2 Inactivated Vaccines
2.2.3 Recombinant Vaccines
2.2.4 Toxoid Vaccines
2.2.5 Virus-like Particles (VLPs) Vaccine Sales by Type
2.2.5.1 Global Virus-like Particles (VLPs) Vaccine Sales Market Share by Type (2021-2026)
2.2.5.2 Global Virus-like Particles (VLPs) Vaccine Revenue and Market Share by Type (2021-2026)
2.2.5.3 Global Virus-like Particles (VLPs) Vaccine Sale Price by Type (2021-2026)
2.3 Virus-like Particles (VLPs) Vaccine Segment by Application
2.3.1 Hepatitis
2.3.2 HPV
2.3.3 Others
2.3.4 Virus-like Particles (VLPs) Vaccine Sales by Application
2.3.4.1 Global Virus-like Particles (VLPs) Vaccine Sale Market Share by Application (2021-2026)
2.3.4.2 Global Virus-like Particles (VLPs) Vaccine Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global Virus-like Particles (VLPs) Vaccine Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Virus-like Particles (VLPs) Vaccine Breakdown Data by Company
3.1.1 Global Virus-like Particles (VLPs) Vaccine Annual Sales by Company (2021-2026)
3.1.2 Global Virus-like Particles (VLPs) Vaccine Sales Market Share by Company (2021-2026)
3.2 Global Virus-like Particles (VLPs) Vaccine Annual Revenue by Company (2021-2026)
3.2.1 Global Virus-like Particles (VLPs) Vaccine Revenue by Company (2021-2026)
3.2.2 Global Virus-like Particles (VLPs) Vaccine Revenue Market Share by Company (2021-2026)
3.3 Global Virus-like Particles (VLPs) Vaccine Sale Price by Company
3.4 Key Manufacturers Virus-like Particles (VLPs) Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Virus-like Particles (VLPs) Vaccine Product Location Distribution
3.4.2 Players Virus-like Particles (VLPs) Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR VIRUS-LIKE PARTICLES (VLPS) VACCINE BY GEOGRAPHIC REGION
4.1 World Historic Virus-like Particles (VLPs) Vaccine Market Size by Geographic Region (2021-2026)
4.1.1 Global Virus-like Particles (VLPs) Vaccine Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Virus-like Particles (VLPs) Vaccine Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Virus-like Particles (VLPs) Vaccine Market Size by Country/Region (2021-2026)
4.2.1 Global Virus-like Particles (VLPs) Vaccine Annual Sales by Country/Region (2021-2026)
4.2.2 Global Virus-like Particles (VLPs) Vaccine Annual Revenue by Country/Region (2021-2026)
4.3 Americas Virus-like Particles (VLPs) Vaccine Sales Growth
4.4 APAC Virus-like Particles (VLPs) Vaccine Sales Growth
4.5 Europe Virus-like Particles (VLPs) Vaccine Sales Growth
4.6 Middle East & Africa Virus-like Particles (VLPs) Vaccine Sales Growth
5 AMERICAS
5.1 Americas Virus-like Particles (VLPs) Vaccine Sales by Country
5.1.1 Americas Virus-like Particles (VLPs) Vaccine Sales by Country (2021-2026)
5.1.2 Americas Virus-like Particles (VLPs) Vaccine Revenue by Country (2021-2026)
5.2 Americas Virus-like Particles (VLPs) Vaccine Sales by Type (2021-2026)
5.3 Americas Virus-like Particles (VLPs) Vaccine Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Virus-like Particles (VLPs) Vaccine Sales by Region
6.1.1 APAC Virus-like Particles (VLPs) Vaccine Sales by Region (2021-2026)
6.1.2 APAC Virus-like Particles (VLPs) Vaccine Revenue by Region (2021-2026)
6.2 APAC Virus-like Particles (VLPs) Vaccine Sales by Type (2021-2026)
6.3 APAC Virus-like Particles (VLPs) Vaccine Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Virus-like Particles (VLPs) Vaccine by Country
7.1.1 Europe Virus-like Particles (VLPs) Vaccine Sales by Country (2021-2026)
7.1.2 Europe Virus-like Particles (VLPs) Vaccine Revenue by Country (2021-2026)
7.2 Europe Virus-like Particles (VLPs) Vaccine Sales by Type (2021-2026)
7.3 Europe Virus-like Particles (VLPs) Vaccine Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Virus-like Particles (VLPs) Vaccine by Country
8.1.1 Middle East & Africa Virus-like Particles (VLPs) Vaccine Sales by Country (2021-2026)
8.1.2 Middle East & Africa Virus-like Particles (VLPs) Vaccine Revenue by Country (2021-2026)
8.2 Middle East & Africa Virus-like Particles (VLPs) Vaccine Sales by Type (2021-2026)
8.3 Middle East & Africa Virus-like Particles (VLPs) Vaccine Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Virus-like Particles (VLPs) Vaccine
10.3 Manufacturing Process Analysis of Virus-like Particles (VLPs) Vaccine
10.4 Industry Chain Structure of Virus-like Particles (VLPs) Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Virus-like Particles (VLPs) Vaccine Distributors
11.3 Virus-like Particles (VLPs) Vaccine Customer
12 WORLD FORECAST REVIEW FOR VIRUS-LIKE PARTICLES (VLPS) VACCINE BY GEOGRAPHIC REGION
12.1 Global Virus-like Particles (VLPs) Vaccine Market Size Forecast by Region
12.1.1 Global Virus-like Particles (VLPs) Vaccine Forecast by Region (2027-2032)
12.1.2 Global Virus-like Particles (VLPs) Vaccine Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Virus-like Particles (VLPs) Vaccine Forecast by Type (2027-2032)
12.7 Global Virus-like Particles (VLPs) Vaccine Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Merck and Co.
13.1.1 Merck and Co. Company Information
13.1.2 Merck and Co. Virus-like Particles (VLPs) Vaccine Product Portfolios and Specifications
13.1.3 Merck and Co. Virus-like Particles (VLPs) Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Merck and Co. Main Business Overview
13.1.5 Merck and Co. Latest Developments
13.2 GlaxoSmithKline
13.2.1 GlaxoSmithKline Company Information
13.2.2 GlaxoSmithKline Virus-like Particles (VLPs) Vaccine Product Portfolios and Specifications
13.2.3 GlaxoSmithKline Virus-like Particles (VLPs) Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 GlaxoSmithKline Main Business Overview
13.2.5 GlaxoSmithKline Latest Developments
13.3 Pfizer
13.3.1 Pfizer Company Information
13.3.2 Pfizer Virus-like Particles (VLPs) Vaccine Product Portfolios and Specifications
13.3.3 Pfizer Virus-like Particles (VLPs) Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Pfizer Main Business Overview
13.3.5 Pfizer Latest Developments
13.4 Dynavax Technologies
13.4.1 Dynavax Technologies Company Information
13.4.2 Dynavax Technologies Virus-like Particles (VLPs) Vaccine Product Portfolios and Specifications
13.4.3 Dynavax Technologies Virus-like Particles (VLPs) Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Dynavax Technologies Main Business Overview
13.4.5 Dynavax Technologies Latest Developments
13.5 Sanofi
13.5.1 Sanofi Company Information
13.5.2 Sanofi Virus-like Particles (VLPs) Vaccine Product Portfolios and Specifications
13.5.3 Sanofi Virus-like Particles (VLPs) Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Sanofi Main Business Overview
13.5.5 Sanofi Latest Developments
13.6 Wantai BioPharm
13.6.1 Wantai BioPharm Company Information
13.6.2 Wantai BioPharm Virus-like Particles (VLPs) Vaccine Product Portfolios and Specifications
13.6.3 Wantai BioPharm Virus-like Particles (VLPs) Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Wantai BioPharm Main Business Overview
13.6.5 Wantai BioPharm Latest Developments
13.7 Serum Institute of India
13.7.1 Serum Institute of India Company Information
13.7.2 Serum Institute of India Virus-like Particles (VLPs) Vaccine Product Portfolios and Specifications
13.7.3 Serum Institute of India Virus-like Particles (VLPs) Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Serum Institute of India Main Business Overview
13.7.5 Serum Institute of India Latest Developments
13.8 Bharat Biotech
13.8.1 Bharat Biotech Company Information
13.8.2 Bharat Biotech Virus-like Particles (VLPs) Vaccine Product Portfolios and Specifications
13.8.3 Bharat Biotech Virus-like Particles (VLPs) Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Bharat Biotech Main Business Overview
13.8.5 Bharat Biotech Latest Developments
13.9 LG Chem
13.9.1 LG Chem Company Information
13.9.2 LG Chem Virus-like Particles (VLPs) Vaccine Product Portfolios and Specifications
13.9.3 LG Chem Virus-like Particles (VLPs) Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 LG Chem Main Business Overview
13.9.5 LG Chem Latest Developments
13.10 VBI Vaccines
13.10.1 VBI Vaccines Company Information
13.10.2 VBI Vaccines Virus-like Particles (VLPs) Vaccine Product Portfolios and Specifications
13.10.3 VBI Vaccines Virus-like Particles (VLPs) Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 VBI Vaccines Main Business Overview
13.10.5 VBI Vaccines Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Virus-like Particles (VLPs) Vaccine Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Virus-like Particles (VLPs) Vaccine by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Virus-like Particles (VLPs) Vaccine by Country/Region, 2021, 2025 & 2032
2.2 Virus-like Particles (VLPs) Vaccine Segment by Type
2.2.1 Live-Attenuated Vaccines
2.2.2 Inactivated Vaccines
2.2.3 Recombinant Vaccines
2.2.4 Toxoid Vaccines
2.2.5 Virus-like Particles (VLPs) Vaccine Sales by Type
2.2.5.1 Global Virus-like Particles (VLPs) Vaccine Sales Market Share by Type (2021-2026)
2.2.5.2 Global Virus-like Particles (VLPs) Vaccine Revenue and Market Share by Type (2021-2026)
2.2.5.3 Global Virus-like Particles (VLPs) Vaccine Sale Price by Type (2021-2026)
2.3 Virus-like Particles (VLPs) Vaccine Segment by Application
2.3.1 Hepatitis
2.3.2 HPV
2.3.3 Others
2.3.4 Virus-like Particles (VLPs) Vaccine Sales by Application
2.3.4.1 Global Virus-like Particles (VLPs) Vaccine Sale Market Share by Application (2021-2026)
2.3.4.2 Global Virus-like Particles (VLPs) Vaccine Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global Virus-like Particles (VLPs) Vaccine Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Virus-like Particles (VLPs) Vaccine Breakdown Data by Company
3.1.1 Global Virus-like Particles (VLPs) Vaccine Annual Sales by Company (2021-2026)
3.1.2 Global Virus-like Particles (VLPs) Vaccine Sales Market Share by Company (2021-2026)
3.2 Global Virus-like Particles (VLPs) Vaccine Annual Revenue by Company (2021-2026)
3.2.1 Global Virus-like Particles (VLPs) Vaccine Revenue by Company (2021-2026)
3.2.2 Global Virus-like Particles (VLPs) Vaccine Revenue Market Share by Company (2021-2026)
3.3 Global Virus-like Particles (VLPs) Vaccine Sale Price by Company
3.4 Key Manufacturers Virus-like Particles (VLPs) Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Virus-like Particles (VLPs) Vaccine Product Location Distribution
3.4.2 Players Virus-like Particles (VLPs) Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR VIRUS-LIKE PARTICLES (VLPS) VACCINE BY GEOGRAPHIC REGION
4.1 World Historic Virus-like Particles (VLPs) Vaccine Market Size by Geographic Region (2021-2026)
4.1.1 Global Virus-like Particles (VLPs) Vaccine Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Virus-like Particles (VLPs) Vaccine Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Virus-like Particles (VLPs) Vaccine Market Size by Country/Region (2021-2026)
4.2.1 Global Virus-like Particles (VLPs) Vaccine Annual Sales by Country/Region (2021-2026)
4.2.2 Global Virus-like Particles (VLPs) Vaccine Annual Revenue by Country/Region (2021-2026)
4.3 Americas Virus-like Particles (VLPs) Vaccine Sales Growth
4.4 APAC Virus-like Particles (VLPs) Vaccine Sales Growth
4.5 Europe Virus-like Particles (VLPs) Vaccine Sales Growth
4.6 Middle East & Africa Virus-like Particles (VLPs) Vaccine Sales Growth
5 AMERICAS
5.1 Americas Virus-like Particles (VLPs) Vaccine Sales by Country
5.1.1 Americas Virus-like Particles (VLPs) Vaccine Sales by Country (2021-2026)
5.1.2 Americas Virus-like Particles (VLPs) Vaccine Revenue by Country (2021-2026)
5.2 Americas Virus-like Particles (VLPs) Vaccine Sales by Type (2021-2026)
5.3 Americas Virus-like Particles (VLPs) Vaccine Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Virus-like Particles (VLPs) Vaccine Sales by Region
6.1.1 APAC Virus-like Particles (VLPs) Vaccine Sales by Region (2021-2026)
6.1.2 APAC Virus-like Particles (VLPs) Vaccine Revenue by Region (2021-2026)
6.2 APAC Virus-like Particles (VLPs) Vaccine Sales by Type (2021-2026)
6.3 APAC Virus-like Particles (VLPs) Vaccine Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Virus-like Particles (VLPs) Vaccine by Country
7.1.1 Europe Virus-like Particles (VLPs) Vaccine Sales by Country (2021-2026)
7.1.2 Europe Virus-like Particles (VLPs) Vaccine Revenue by Country (2021-2026)
7.2 Europe Virus-like Particles (VLPs) Vaccine Sales by Type (2021-2026)
7.3 Europe Virus-like Particles (VLPs) Vaccine Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Virus-like Particles (VLPs) Vaccine by Country
8.1.1 Middle East & Africa Virus-like Particles (VLPs) Vaccine Sales by Country (2021-2026)
8.1.2 Middle East & Africa Virus-like Particles (VLPs) Vaccine Revenue by Country (2021-2026)
8.2 Middle East & Africa Virus-like Particles (VLPs) Vaccine Sales by Type (2021-2026)
8.3 Middle East & Africa Virus-like Particles (VLPs) Vaccine Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Virus-like Particles (VLPs) Vaccine
10.3 Manufacturing Process Analysis of Virus-like Particles (VLPs) Vaccine
10.4 Industry Chain Structure of Virus-like Particles (VLPs) Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Virus-like Particles (VLPs) Vaccine Distributors
11.3 Virus-like Particles (VLPs) Vaccine Customer
12 WORLD FORECAST REVIEW FOR VIRUS-LIKE PARTICLES (VLPS) VACCINE BY GEOGRAPHIC REGION
12.1 Global Virus-like Particles (VLPs) Vaccine Market Size Forecast by Region
12.1.1 Global Virus-like Particles (VLPs) Vaccine Forecast by Region (2027-2032)
12.1.2 Global Virus-like Particles (VLPs) Vaccine Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Virus-like Particles (VLPs) Vaccine Forecast by Type (2027-2032)
12.7 Global Virus-like Particles (VLPs) Vaccine Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Merck and Co.
13.1.1 Merck and Co. Company Information
13.1.2 Merck and Co. Virus-like Particles (VLPs) Vaccine Product Portfolios and Specifications
13.1.3 Merck and Co. Virus-like Particles (VLPs) Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Merck and Co. Main Business Overview
13.1.5 Merck and Co. Latest Developments
13.2 GlaxoSmithKline
13.2.1 GlaxoSmithKline Company Information
13.2.2 GlaxoSmithKline Virus-like Particles (VLPs) Vaccine Product Portfolios and Specifications
13.2.3 GlaxoSmithKline Virus-like Particles (VLPs) Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 GlaxoSmithKline Main Business Overview
13.2.5 GlaxoSmithKline Latest Developments
13.3 Pfizer
13.3.1 Pfizer Company Information
13.3.2 Pfizer Virus-like Particles (VLPs) Vaccine Product Portfolios and Specifications
13.3.3 Pfizer Virus-like Particles (VLPs) Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Pfizer Main Business Overview
13.3.5 Pfizer Latest Developments
13.4 Dynavax Technologies
13.4.1 Dynavax Technologies Company Information
13.4.2 Dynavax Technologies Virus-like Particles (VLPs) Vaccine Product Portfolios and Specifications
13.4.3 Dynavax Technologies Virus-like Particles (VLPs) Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Dynavax Technologies Main Business Overview
13.4.5 Dynavax Technologies Latest Developments
13.5 Sanofi
13.5.1 Sanofi Company Information
13.5.2 Sanofi Virus-like Particles (VLPs) Vaccine Product Portfolios and Specifications
13.5.3 Sanofi Virus-like Particles (VLPs) Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Sanofi Main Business Overview
13.5.5 Sanofi Latest Developments
13.6 Wantai BioPharm
13.6.1 Wantai BioPharm Company Information
13.6.2 Wantai BioPharm Virus-like Particles (VLPs) Vaccine Product Portfolios and Specifications
13.6.3 Wantai BioPharm Virus-like Particles (VLPs) Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Wantai BioPharm Main Business Overview
13.6.5 Wantai BioPharm Latest Developments
13.7 Serum Institute of India
13.7.1 Serum Institute of India Company Information
13.7.2 Serum Institute of India Virus-like Particles (VLPs) Vaccine Product Portfolios and Specifications
13.7.3 Serum Institute of India Virus-like Particles (VLPs) Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Serum Institute of India Main Business Overview
13.7.5 Serum Institute of India Latest Developments
13.8 Bharat Biotech
13.8.1 Bharat Biotech Company Information
13.8.2 Bharat Biotech Virus-like Particles (VLPs) Vaccine Product Portfolios and Specifications
13.8.3 Bharat Biotech Virus-like Particles (VLPs) Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Bharat Biotech Main Business Overview
13.8.5 Bharat Biotech Latest Developments
13.9 LG Chem
13.9.1 LG Chem Company Information
13.9.2 LG Chem Virus-like Particles (VLPs) Vaccine Product Portfolios and Specifications
13.9.3 LG Chem Virus-like Particles (VLPs) Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 LG Chem Main Business Overview
13.9.5 LG Chem Latest Developments
13.10 VBI Vaccines
13.10.1 VBI Vaccines Company Information
13.10.2 VBI Vaccines Virus-like Particles (VLPs) Vaccine Product Portfolios and Specifications
13.10.3 VBI Vaccines Virus-like Particles (VLPs) Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 VBI Vaccines Main Business Overview
13.10.5 VBI Vaccines Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Virus-like Particles (VLPs) Vaccine Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Virus-like Particles (VLPs) Vaccine Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Live-Attenuated Vaccines
Table 4. Major Players of Inactivated Vaccines
Table 5. Major Players of Recombinant Vaccines
Table 6. Major Players of Toxoid Vaccines
Table 7. Global Virus-like Particles (VLPs) Vaccine Sales by Type (2021-2026) & (K Units)
Table 8. Global Virus-like Particles (VLPs) Vaccine Sales Market Share by Type (2021-2026)
Table 9. Global Virus-like Particles (VLPs) Vaccine Revenue by Type (2021-2026) & ($ million)
Table 10. Global Virus-like Particles (VLPs) Vaccine Revenue Market Share by Type (2021-2026)
Table 11. Global Virus-like Particles (VLPs) Vaccine Sale Price by Type (2021-2026) & (US$/Unit)
Table 12. Global Virus-like Particles (VLPs) Vaccine Sale by Application (2021-2026) & (K Units)
Table 13. Global Virus-like Particles (VLPs) Vaccine Sale Market Share by Application (2021-2026)
Table 14. Global Virus-like Particles (VLPs) Vaccine Revenue by Application (2021-2026) & ($ million)
Table 15. Global Virus-like Particles (VLPs) Vaccine Revenue Market Share by Application (2021-2026)
Table 16. Global Virus-like Particles (VLPs) Vaccine Sale Price by Application (2021-2026) & (US$/Unit)
Table 17. Global Virus-like Particles (VLPs) Vaccine Sales by Company (2021-2026) & (K Units)
Table 18. Global Virus-like Particles (VLPs) Vaccine Sales Market Share by Company (2021-2026)
Table 19. Global Virus-like Particles (VLPs) Vaccine Revenue by Company (2021-2026) & ($ millions)
Table 20. Global Virus-like Particles (VLPs) Vaccine Revenue Market Share by Company (2021-2026)
Table 21. Global Virus-like Particles (VLPs) Vaccine Sale Price by Company (2021-2026) & (US$/Unit)
Table 22. Key Manufacturers Virus-like Particles (VLPs) Vaccine Producing Area Distribution and Sales Area
Table 23. Players Virus-like Particles (VLPs) Vaccine Products Offered
Table 24. Virus-like Particles (VLPs) Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 25. New Products and Potential Entrants
Table 26. Market M&A Activity & Strategy
Table 27. Global Virus-like Particles (VLPs) Vaccine Sales by Geographic Region (2021-2026) & (K Units)
Table 28. Global Virus-like Particles (VLPs) Vaccine Sales Market Share Geographic Region (2021-2026)
Table 29. Global Virus-like Particles (VLPs) Vaccine Revenue by Geographic Region (2021-2026) & ($ millions)
Table 30. Global Virus-like Particles (VLPs) Vaccine Revenue Market Share by Geographic Region (2021-2026)
Table 31. Global Virus-like Particles (VLPs) Vaccine Sales by Country/Region (2021-2026) & (K Units)
Table 32. Global Virus-like Particles (VLPs) Vaccine Sales Market Share by Country/Region (2021-2026)
Table 33. Global Virus-like Particles (VLPs) Vaccine Revenue by Country/Region (2021-2026) & ($ millions)
Table 34. Global Virus-like Particles (VLPs) Vaccine Revenue Market Share by Country/Region (2021-2026)
Table 35. Americas Virus-like Particles (VLPs) Vaccine Sales by Country (2021-2026) & (K Units)
Table 36. Americas Virus-like Particles (VLPs) Vaccine Sales Market Share by Country (2021-2026)
Table 37. Americas Virus-like Particles (VLPs) Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 38. Americas Virus-like Particles (VLPs) Vaccine Sales by Type (2021-2026) & (K Units)
Table 39. Americas Virus-like Particles (VLPs) Vaccine Sales by Application (2021-2026) & (K Units)
Table 40. APAC Virus-like Particles (VLPs) Vaccine Sales by Region (2021-2026) & (K Units)
Table 41. APAC Virus-like Particles (VLPs) Vaccine Sales Market Share by Region (2021-2026)
Table 42. APAC Virus-like Particles (VLPs) Vaccine Revenue by Region (2021-2026) & ($ millions)
Table 43. APAC Virus-like Particles (VLPs) Vaccine Sales by Type (2021-2026) & (K Units)
Table 44. APAC Virus-like Particles (VLPs) Vaccine Sales by Application (2021-2026) & (K Units)
Table 45. Europe Virus-like Particles (VLPs) Vaccine Sales by Country (2021-2026) & (K Units)
Table 46. Europe Virus-like Particles (VLPs) Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 47. Europe Virus-like Particles (VLPs) Vaccine Sales by Type (2021-2026) & (K Units)
Table 48. Europe Virus-like Particles (VLPs) Vaccine Sales by Application (2021-2026) & (K Units)
Table 49. Middle East & Africa Virus-like Particles (VLPs) Vaccine Sales by Country (2021-2026) & (K Units)
Table 50. Middle East & Africa Virus-like Particles (VLPs) Vaccine Revenue Market Share by Country (2021-2026)
Table 51. Middle East & Africa Virus-like Particles (VLPs) Vaccine Sales by Type (2021-2026) & (K Units)
Table 52. Middle East & Africa Virus-like Particles (VLPs) Vaccine Sales by Application (2021-2026) & (K Units)
Table 53. Key Market Drivers & Growth Opportunities of Virus-like Particles (VLPs) Vaccine
Table 54. Key Market Challenges & Risks of Virus-like Particles (VLPs) Vaccine
Table 55. Key Industry Trends of Virus-like Particles (VLPs) Vaccine
Table 56. Virus-like Particles (VLPs) Vaccine Raw Material
Table 57. Key Suppliers of Raw Materials
Table 58. Virus-like Particles (VLPs) Vaccine Distributors List
Table 59. Virus-like Particles (VLPs) Vaccine Customer List
Table 60. Global Virus-like Particles (VLPs) Vaccine Sales Forecast by Region (2027-2032) & (K Units)
Table 61. Global Virus-like Particles (VLPs) Vaccine Revenue Forecast by Region (2027-2032) & ($ millions)
Table 62. Americas Virus-like Particles (VLPs) Vaccine Sales Forecast by Country (2027-2032) & (K Units)
Table 63. Americas Virus-like Particles (VLPs) Vaccine Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 64. APAC Virus-like Particles (VLPs) Vaccine Sales Forecast by Region (2027-2032) & (K Units)
Table 65. APAC Virus-like Particles (VLPs) Vaccine Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 66. Europe Virus-like Particles (VLPs) Vaccine Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Europe Virus-like Particles (VLPs) Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Middle East & Africa Virus-like Particles (VLPs) Vaccine Sales Forecast by Country (2027-2032) & (K Units)
Table 69. Middle East & Africa Virus-like Particles (VLPs) Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 70. Global Virus-like Particles (VLPs) Vaccine Sales Forecast by Type (2027-2032) & (K Units)
Table 71. Global Virus-like Particles (VLPs) Vaccine Revenue Forecast by Type (2027-2032) & ($ millions)
Table 72. Global Virus-like Particles (VLPs) Vaccine Sales Forecast by Application (2027-2032) & (K Units)
Table 73. Global Virus-like Particles (VLPs) Vaccine Revenue Forecast by Application (2027-2032) & ($ millions)
Table 74. Merck and Co. Basic Information, Virus-like Particles (VLPs) Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 75. Merck and Co. Virus-like Particles (VLPs) Vaccine Product Portfolios and Specifications
Table 76. Merck and Co. Virus-like Particles (VLPs) Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 77. Merck and Co. Main Business
Table 78. Merck and Co. Latest Developments
Table 79. GlaxoSmithKline Basic Information, Virus-like Particles (VLPs) Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 80. GlaxoSmithKline Virus-like Particles (VLPs) Vaccine Product Portfolios and Specifications
Table 81. GlaxoSmithKline Virus-like Particles (VLPs) Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 82. GlaxoSmithKline Main Business
Table 83. GlaxoSmithKline Latest Developments
Table 84. Pfizer Basic Information, Virus-like Particles (VLPs) Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 85. Pfizer Virus-like Particles (VLPs) Vaccine Product Portfolios and Specifications
Table 86. Pfizer Virus-like Particles (VLPs) Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 87. Pfizer Main Business
Table 88. Pfizer Latest Developments
Table 89. Dynavax Technologies Basic Information, Virus-like Particles (VLPs) Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 90. Dynavax Technologies Virus-like Particles (VLPs) Vaccine Product Portfolios and Specifications
Table 91. Dynavax Technologies Virus-like Particles (VLPs) Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 92. Dynavax Technologies Main Business
Table 93. Dynavax Technologies Latest Developments
Table 94. Sanofi Basic Information, Virus-like Particles (VLPs) Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 95. Sanofi Virus-like Particles (VLPs) Vaccine Product Portfolios and Specifications
Table 96. Sanofi Virus-like Particles (VLPs) Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 97. Sanofi Main Business
Table 98. Sanofi Latest Developments
Table 99. Wantai BioPharm Basic Information, Virus-like Particles (VLPs) Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 100. Wantai BioPharm Virus-like Particles (VLPs) Vaccine Product Portfolios and Specifications
Table 101. Wantai BioPharm Virus-like Particles (VLPs) Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 102. Wantai BioPharm Main Business
Table 103. Wantai BioPharm Latest Developments
Table 104. Serum Institute of India Basic Information, Virus-like Particles (VLPs) Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 105. Serum Institute of India Virus-like Particles (VLPs) Vaccine Product Portfolios and Specifications
Table 106. Serum Institute of India Virus-like Particles (VLPs) Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 107. Serum Institute of India Main Business
Table 108. Serum Institute of India Latest Developments
Table 109. Bharat Biotech Basic Information, Virus-like Particles (VLPs) Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 110. Bharat Biotech Virus-like Particles (VLPs) Vaccine Product Portfolios and Specifications
Table 111. Bharat Biotech Virus-like Particles (VLPs) Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 112. Bharat Biotech Main Business
Table 113. Bharat Biotech Latest Developments
Table 114. LG Chem Basic Information, Virus-like Particles (VLPs) Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 115. LG Chem Virus-like Particles (VLPs) Vaccine Product Portfolios and Specifications
Table 116. LG Chem Virus-like Particles (VLPs) Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 117. LG Chem Main Business
Table 118. LG Chem Latest Developments
Table 119. VBI Vaccines Basic Information, Virus-like Particles (VLPs) Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 120. VBI Vaccines Virus-like Particles (VLPs) Vaccine Product Portfolios and Specifications
Table 121. VBI Vaccines Virus-like Particles (VLPs) Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 122. VBI Vaccines Main Business
Table 123. VBI Vaccines Latest Developments
Table 1. Virus-like Particles (VLPs) Vaccine Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Virus-like Particles (VLPs) Vaccine Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Live-Attenuated Vaccines
Table 4. Major Players of Inactivated Vaccines
Table 5. Major Players of Recombinant Vaccines
Table 6. Major Players of Toxoid Vaccines
Table 7. Global Virus-like Particles (VLPs) Vaccine Sales by Type (2021-2026) & (K Units)
Table 8. Global Virus-like Particles (VLPs) Vaccine Sales Market Share by Type (2021-2026)
Table 9. Global Virus-like Particles (VLPs) Vaccine Revenue by Type (2021-2026) & ($ million)
Table 10. Global Virus-like Particles (VLPs) Vaccine Revenue Market Share by Type (2021-2026)
Table 11. Global Virus-like Particles (VLPs) Vaccine Sale Price by Type (2021-2026) & (US$/Unit)
Table 12. Global Virus-like Particles (VLPs) Vaccine Sale by Application (2021-2026) & (K Units)
Table 13. Global Virus-like Particles (VLPs) Vaccine Sale Market Share by Application (2021-2026)
Table 14. Global Virus-like Particles (VLPs) Vaccine Revenue by Application (2021-2026) & ($ million)
Table 15. Global Virus-like Particles (VLPs) Vaccine Revenue Market Share by Application (2021-2026)
Table 16. Global Virus-like Particles (VLPs) Vaccine Sale Price by Application (2021-2026) & (US$/Unit)
Table 17. Global Virus-like Particles (VLPs) Vaccine Sales by Company (2021-2026) & (K Units)
Table 18. Global Virus-like Particles (VLPs) Vaccine Sales Market Share by Company (2021-2026)
Table 19. Global Virus-like Particles (VLPs) Vaccine Revenue by Company (2021-2026) & ($ millions)
Table 20. Global Virus-like Particles (VLPs) Vaccine Revenue Market Share by Company (2021-2026)
Table 21. Global Virus-like Particles (VLPs) Vaccine Sale Price by Company (2021-2026) & (US$/Unit)
Table 22. Key Manufacturers Virus-like Particles (VLPs) Vaccine Producing Area Distribution and Sales Area
Table 23. Players Virus-like Particles (VLPs) Vaccine Products Offered
Table 24. Virus-like Particles (VLPs) Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 25. New Products and Potential Entrants
Table 26. Market M&A Activity & Strategy
Table 27. Global Virus-like Particles (VLPs) Vaccine Sales by Geographic Region (2021-2026) & (K Units)
Table 28. Global Virus-like Particles (VLPs) Vaccine Sales Market Share Geographic Region (2021-2026)
Table 29. Global Virus-like Particles (VLPs) Vaccine Revenue by Geographic Region (2021-2026) & ($ millions)
Table 30. Global Virus-like Particles (VLPs) Vaccine Revenue Market Share by Geographic Region (2021-2026)
Table 31. Global Virus-like Particles (VLPs) Vaccine Sales by Country/Region (2021-2026) & (K Units)
Table 32. Global Virus-like Particles (VLPs) Vaccine Sales Market Share by Country/Region (2021-2026)
Table 33. Global Virus-like Particles (VLPs) Vaccine Revenue by Country/Region (2021-2026) & ($ millions)
Table 34. Global Virus-like Particles (VLPs) Vaccine Revenue Market Share by Country/Region (2021-2026)
Table 35. Americas Virus-like Particles (VLPs) Vaccine Sales by Country (2021-2026) & (K Units)
Table 36. Americas Virus-like Particles (VLPs) Vaccine Sales Market Share by Country (2021-2026)
Table 37. Americas Virus-like Particles (VLPs) Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 38. Americas Virus-like Particles (VLPs) Vaccine Sales by Type (2021-2026) & (K Units)
Table 39. Americas Virus-like Particles (VLPs) Vaccine Sales by Application (2021-2026) & (K Units)
Table 40. APAC Virus-like Particles (VLPs) Vaccine Sales by Region (2021-2026) & (K Units)
Table 41. APAC Virus-like Particles (VLPs) Vaccine Sales Market Share by Region (2021-2026)
Table 42. APAC Virus-like Particles (VLPs) Vaccine Revenue by Region (2021-2026) & ($ millions)
Table 43. APAC Virus-like Particles (VLPs) Vaccine Sales by Type (2021-2026) & (K Units)
Table 44. APAC Virus-like Particles (VLPs) Vaccine Sales by Application (2021-2026) & (K Units)
Table 45. Europe Virus-like Particles (VLPs) Vaccine Sales by Country (2021-2026) & (K Units)
Table 46. Europe Virus-like Particles (VLPs) Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 47. Europe Virus-like Particles (VLPs) Vaccine Sales by Type (2021-2026) & (K Units)
Table 48. Europe Virus-like Particles (VLPs) Vaccine Sales by Application (2021-2026) & (K Units)
Table 49. Middle East & Africa Virus-like Particles (VLPs) Vaccine Sales by Country (2021-2026) & (K Units)
Table 50. Middle East & Africa Virus-like Particles (VLPs) Vaccine Revenue Market Share by Country (2021-2026)
Table 51. Middle East & Africa Virus-like Particles (VLPs) Vaccine Sales by Type (2021-2026) & (K Units)
Table 52. Middle East & Africa Virus-like Particles (VLPs) Vaccine Sales by Application (2021-2026) & (K Units)
Table 53. Key Market Drivers & Growth Opportunities of Virus-like Particles (VLPs) Vaccine
Table 54. Key Market Challenges & Risks of Virus-like Particles (VLPs) Vaccine
Table 55. Key Industry Trends of Virus-like Particles (VLPs) Vaccine
Table 56. Virus-like Particles (VLPs) Vaccine Raw Material
Table 57. Key Suppliers of Raw Materials
Table 58. Virus-like Particles (VLPs) Vaccine Distributors List
Table 59. Virus-like Particles (VLPs) Vaccine Customer List
Table 60. Global Virus-like Particles (VLPs) Vaccine Sales Forecast by Region (2027-2032) & (K Units)
Table 61. Global Virus-like Particles (VLPs) Vaccine Revenue Forecast by Region (2027-2032) & ($ millions)
Table 62. Americas Virus-like Particles (VLPs) Vaccine Sales Forecast by Country (2027-2032) & (K Units)
Table 63. Americas Virus-like Particles (VLPs) Vaccine Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 64. APAC Virus-like Particles (VLPs) Vaccine Sales Forecast by Region (2027-2032) & (K Units)
Table 65. APAC Virus-like Particles (VLPs) Vaccine Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 66. Europe Virus-like Particles (VLPs) Vaccine Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Europe Virus-like Particles (VLPs) Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Middle East & Africa Virus-like Particles (VLPs) Vaccine Sales Forecast by Country (2027-2032) & (K Units)
Table 69. Middle East & Africa Virus-like Particles (VLPs) Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 70. Global Virus-like Particles (VLPs) Vaccine Sales Forecast by Type (2027-2032) & (K Units)
Table 71. Global Virus-like Particles (VLPs) Vaccine Revenue Forecast by Type (2027-2032) & ($ millions)
Table 72. Global Virus-like Particles (VLPs) Vaccine Sales Forecast by Application (2027-2032) & (K Units)
Table 73. Global Virus-like Particles (VLPs) Vaccine Revenue Forecast by Application (2027-2032) & ($ millions)
Table 74. Merck and Co. Basic Information, Virus-like Particles (VLPs) Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 75. Merck and Co. Virus-like Particles (VLPs) Vaccine Product Portfolios and Specifications
Table 76. Merck and Co. Virus-like Particles (VLPs) Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 77. Merck and Co. Main Business
Table 78. Merck and Co. Latest Developments
Table 79. GlaxoSmithKline Basic Information, Virus-like Particles (VLPs) Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 80. GlaxoSmithKline Virus-like Particles (VLPs) Vaccine Product Portfolios and Specifications
Table 81. GlaxoSmithKline Virus-like Particles (VLPs) Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 82. GlaxoSmithKline Main Business
Table 83. GlaxoSmithKline Latest Developments
Table 84. Pfizer Basic Information, Virus-like Particles (VLPs) Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 85. Pfizer Virus-like Particles (VLPs) Vaccine Product Portfolios and Specifications
Table 86. Pfizer Virus-like Particles (VLPs) Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 87. Pfizer Main Business
Table 88. Pfizer Latest Developments
Table 89. Dynavax Technologies Basic Information, Virus-like Particles (VLPs) Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 90. Dynavax Technologies Virus-like Particles (VLPs) Vaccine Product Portfolios and Specifications
Table 91. Dynavax Technologies Virus-like Particles (VLPs) Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 92. Dynavax Technologies Main Business
Table 93. Dynavax Technologies Latest Developments
Table 94. Sanofi Basic Information, Virus-like Particles (VLPs) Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 95. Sanofi Virus-like Particles (VLPs) Vaccine Product Portfolios and Specifications
Table 96. Sanofi Virus-like Particles (VLPs) Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 97. Sanofi Main Business
Table 98. Sanofi Latest Developments
Table 99. Wantai BioPharm Basic Information, Virus-like Particles (VLPs) Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 100. Wantai BioPharm Virus-like Particles (VLPs) Vaccine Product Portfolios and Specifications
Table 101. Wantai BioPharm Virus-like Particles (VLPs) Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 102. Wantai BioPharm Main Business
Table 103. Wantai BioPharm Latest Developments
Table 104. Serum Institute of India Basic Information, Virus-like Particles (VLPs) Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 105. Serum Institute of India Virus-like Particles (VLPs) Vaccine Product Portfolios and Specifications
Table 106. Serum Institute of India Virus-like Particles (VLPs) Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 107. Serum Institute of India Main Business
Table 108. Serum Institute of India Latest Developments
Table 109. Bharat Biotech Basic Information, Virus-like Particles (VLPs) Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 110. Bharat Biotech Virus-like Particles (VLPs) Vaccine Product Portfolios and Specifications
Table 111. Bharat Biotech Virus-like Particles (VLPs) Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 112. Bharat Biotech Main Business
Table 113. Bharat Biotech Latest Developments
Table 114. LG Chem Basic Information, Virus-like Particles (VLPs) Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 115. LG Chem Virus-like Particles (VLPs) Vaccine Product Portfolios and Specifications
Table 116. LG Chem Virus-like Particles (VLPs) Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 117. LG Chem Main Business
Table 118. LG Chem Latest Developments
Table 119. VBI Vaccines Basic Information, Virus-like Particles (VLPs) Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 120. VBI Vaccines Virus-like Particles (VLPs) Vaccine Product Portfolios and Specifications
Table 121. VBI Vaccines Virus-like Particles (VLPs) Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 122. VBI Vaccines Main Business
Table 123. VBI Vaccines Latest Developments
LIST OF FIGURES
Figure 1. Picture of Virus-like Particles (VLPs) Vaccine
Figure 2. Virus-like Particles (VLPs) Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Virus-like Particles (VLPs) Vaccine Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Virus-like Particles (VLPs) Vaccine Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Virus-like Particles (VLPs) Vaccine Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Virus-like Particles (VLPs) Vaccine Sales Market Share by Country/Region (2025)
Figure 10. Virus-like Particles (VLPs) Vaccine Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Live-Attenuated Vaccines
Figure 12. Product Picture of Inactivated Vaccines
Figure 13. Product Picture of Recombinant Vaccines
Figure 14. Product Picture of Toxoid Vaccines
Figure 15. Global Virus-like Particles (VLPs) Vaccine Sales Market Share by Type in 2026
Figure 16. Global Virus-like Particles (VLPs) Vaccine Revenue Market Share by Type (2021-2026)
Figure 17. Virus-like Particles (VLPs) Vaccine Consumed in Hepatitis
Figure 18. Global Virus-like Particles (VLPs) Vaccine Market: Hepatitis (2021-2026) & (K Units)
Figure 19. Virus-like Particles (VLPs) Vaccine Consumed in HPV
Figure 20. Global Virus-like Particles (VLPs) Vaccine Market: HPV (2021-2026) & (K Units)
Figure 21. Virus-like Particles (VLPs) Vaccine Consumed in Others
Figure 22. Global Virus-like Particles (VLPs) Vaccine Market: Others (2021-2026) & (K Units)
Figure 23. Global Virus-like Particles (VLPs) Vaccine Sale Market Share by Application (2025)
Figure 24. Global Virus-like Particles (VLPs) Vaccine Revenue Market Share by Application in 2026
Figure 25. Virus-like Particles (VLPs) Vaccine Sales by Company in 2026 (K Units)
Figure 26. Global Virus-like Particles (VLPs) Vaccine Sales Market Share by Company in 2026
Figure 27. Virus-like Particles (VLPs) Vaccine Revenue by Company in 2026 ($ millions)
Figure 28. Global Virus-like Particles (VLPs) Vaccine Revenue Market Share by Company in 2026
Figure 29. Global Virus-like Particles (VLPs) Vaccine Sales Market Share by Geographic Region (2021-2026)
Figure 30. Global Virus-like Particles (VLPs) Vaccine Revenue Market Share by Geographic Region in 2026
Figure 31. Americas Virus-like Particles (VLPs) Vaccine Sales 2021-2026 (K Units)
Figure 32. Americas Virus-like Particles (VLPs) Vaccine Revenue 2021-2026 ($ millions)
Figure 33. APAC Virus-like Particles (VLPs) Vaccine Sales 2021-2026 (K Units)
Figure 34. APAC Virus-like Particles (VLPs) Vaccine Revenue 2021-2026 ($ millions)
Figure 35. Europe Virus-like Particles (VLPs) Vaccine Sales 2021-2026 (K Units)
Figure 36. Europe Virus-like Particles (VLPs) Vaccine Revenue 2021-2026 ($ millions)
Figure 37. Middle East & Africa Virus-like Particles (VLPs) Vaccine Sales 2021-2026 (K Units)
Figure 38. Middle East & Africa Virus-like Particles (VLPs) Vaccine Revenue 2021-2026 ($ millions)
Figure 39. Americas Virus-like Particles (VLPs) Vaccine Sales Market Share by Country in 2026
Figure 40. Americas Virus-like Particles (VLPs) Vaccine Revenue Market Share by Country (2021-2026)
Figure 41. Americas Virus-like Particles (VLPs) Vaccine Sales Market Share by Type (2021-2026)
Figure 42. Americas Virus-like Particles (VLPs) Vaccine Sales Market Share by Application (2021-2026)
Figure 43. United States Virus-like Particles (VLPs) Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 44. Canada Virus-like Particles (VLPs) Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 45. Mexico Virus-like Particles (VLPs) Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 46. Brazil Virus-like Particles (VLPs) Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 47. APAC Virus-like Particles (VLPs) Vaccine Sales Market Share by Region in 2026
Figure 48. APAC Virus-like Particles (VLPs) Vaccine Revenue Market Share by Region (2021-2026)
Figure 49. APAC Virus-like Particles (VLPs) Vaccine Sales Market Share by Type (2021-2026)
Figure 50. APAC Virus-like Particles (VLPs) Vaccine Sales Market Share by Application (2021-2026)
Figure 51. China Virus-like Particles (VLPs) Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 52. Japan Virus-like Particles (VLPs) Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 53. South Korea Virus-like Particles (VLPs) Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 54. Southeast Asia Virus-like Particles (VLPs) Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 55. India Virus-like Particles (VLPs) Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 56. Australia Virus-like Particles (VLPs) Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 57. China Taiwan Virus-like Particles (VLPs) Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 58. Europe Virus-like Particles (VLPs) Vaccine Sales Market Share by Country in 2026
Figure 59. Europe Virus-like Particles (VLPs) Vaccine Revenue Market Share by Country (2021-2026)
Figure 60. Europe Virus-like Particles (VLPs) Vaccine Sales Market Share by Type (2021-2026)
Figure 61. Europe Virus-like Particles (VLPs) Vaccine Sales Market Share by Application (2021-2026)
Figure 62. Germany Virus-like Particles (VLPs) Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 63. France Virus-like Particles (VLPs) Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 64. UK Virus-like Particles (VLPs) Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 65. Italy Virus-like Particles (VLPs) Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 66. Russia Virus-like Particles (VLPs) Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 67. Middle East & Africa Virus-like Particles (VLPs) Vaccine Sales Market Share by Country (2021-2026)
Figure 68. Middle East & Africa Virus-like Particles (VLPs) Vaccine Sales Market Share by Type (2021-2026)
Figure 69. Middle East & Africa Virus-like Particles (VLPs) Vaccine Sales Market Share by Application (2021-2026)
Figure 70. Egypt Virus-like Particles (VLPs) Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 71. South Africa Virus-like Particles (VLPs) Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 72. Israel Virus-like Particles (VLPs) Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 73. Turkey Virus-like Particles (VLPs) Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 74. GCC Countries Virus-like Particles (VLPs) Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 75. Manufacturing Cost Structure Analysis of Virus-like Particles (VLPs) Vaccine in 2026
Figure 76. Manufacturing Process Analysis of Virus-like Particles (VLPs) Vaccine
Figure 77. Industry Chain Structure of Virus-like Particles (VLPs) Vaccine
Figure 78. Channels of Distribution
Figure 79. Global Virus-like Particles (VLPs) Vaccine Sales Market Forecast by Region (2027-2032)
Figure 80. Global Virus-like Particles (VLPs) Vaccine Revenue Market Share Forecast by Region (2027-2032)
Figure 81. Global Virus-like Particles (VLPs) Vaccine Sales Market Share Forecast by Type (2027-2032)
Figure 82. Global Virus-like Particles (VLPs) Vaccine Revenue Market Share Forecast by Type (2027-2032)
Figure 83. Global Virus-like Particles (VLPs) Vaccine Sales Market Share Forecast by Application (2027-2032)
Figure 84. Global Virus-like Particles (VLPs) Vaccine Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Virus-like Particles (VLPs) Vaccine
Figure 2. Virus-like Particles (VLPs) Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Virus-like Particles (VLPs) Vaccine Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Virus-like Particles (VLPs) Vaccine Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Virus-like Particles (VLPs) Vaccine Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Virus-like Particles (VLPs) Vaccine Sales Market Share by Country/Region (2025)
Figure 10. Virus-like Particles (VLPs) Vaccine Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Live-Attenuated Vaccines
Figure 12. Product Picture of Inactivated Vaccines
Figure 13. Product Picture of Recombinant Vaccines
Figure 14. Product Picture of Toxoid Vaccines
Figure 15. Global Virus-like Particles (VLPs) Vaccine Sales Market Share by Type in 2026
Figure 16. Global Virus-like Particles (VLPs) Vaccine Revenue Market Share by Type (2021-2026)
Figure 17. Virus-like Particles (VLPs) Vaccine Consumed in Hepatitis
Figure 18. Global Virus-like Particles (VLPs) Vaccine Market: Hepatitis (2021-2026) & (K Units)
Figure 19. Virus-like Particles (VLPs) Vaccine Consumed in HPV
Figure 20. Global Virus-like Particles (VLPs) Vaccine Market: HPV (2021-2026) & (K Units)
Figure 21. Virus-like Particles (VLPs) Vaccine Consumed in Others
Figure 22. Global Virus-like Particles (VLPs) Vaccine Market: Others (2021-2026) & (K Units)
Figure 23. Global Virus-like Particles (VLPs) Vaccine Sale Market Share by Application (2025)
Figure 24. Global Virus-like Particles (VLPs) Vaccine Revenue Market Share by Application in 2026
Figure 25. Virus-like Particles (VLPs) Vaccine Sales by Company in 2026 (K Units)
Figure 26. Global Virus-like Particles (VLPs) Vaccine Sales Market Share by Company in 2026
Figure 27. Virus-like Particles (VLPs) Vaccine Revenue by Company in 2026 ($ millions)
Figure 28. Global Virus-like Particles (VLPs) Vaccine Revenue Market Share by Company in 2026
Figure 29. Global Virus-like Particles (VLPs) Vaccine Sales Market Share by Geographic Region (2021-2026)
Figure 30. Global Virus-like Particles (VLPs) Vaccine Revenue Market Share by Geographic Region in 2026
Figure 31. Americas Virus-like Particles (VLPs) Vaccine Sales 2021-2026 (K Units)
Figure 32. Americas Virus-like Particles (VLPs) Vaccine Revenue 2021-2026 ($ millions)
Figure 33. APAC Virus-like Particles (VLPs) Vaccine Sales 2021-2026 (K Units)
Figure 34. APAC Virus-like Particles (VLPs) Vaccine Revenue 2021-2026 ($ millions)
Figure 35. Europe Virus-like Particles (VLPs) Vaccine Sales 2021-2026 (K Units)
Figure 36. Europe Virus-like Particles (VLPs) Vaccine Revenue 2021-2026 ($ millions)
Figure 37. Middle East & Africa Virus-like Particles (VLPs) Vaccine Sales 2021-2026 (K Units)
Figure 38. Middle East & Africa Virus-like Particles (VLPs) Vaccine Revenue 2021-2026 ($ millions)
Figure 39. Americas Virus-like Particles (VLPs) Vaccine Sales Market Share by Country in 2026
Figure 40. Americas Virus-like Particles (VLPs) Vaccine Revenue Market Share by Country (2021-2026)
Figure 41. Americas Virus-like Particles (VLPs) Vaccine Sales Market Share by Type (2021-2026)
Figure 42. Americas Virus-like Particles (VLPs) Vaccine Sales Market Share by Application (2021-2026)
Figure 43. United States Virus-like Particles (VLPs) Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 44. Canada Virus-like Particles (VLPs) Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 45. Mexico Virus-like Particles (VLPs) Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 46. Brazil Virus-like Particles (VLPs) Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 47. APAC Virus-like Particles (VLPs) Vaccine Sales Market Share by Region in 2026
Figure 48. APAC Virus-like Particles (VLPs) Vaccine Revenue Market Share by Region (2021-2026)
Figure 49. APAC Virus-like Particles (VLPs) Vaccine Sales Market Share by Type (2021-2026)
Figure 50. APAC Virus-like Particles (VLPs) Vaccine Sales Market Share by Application (2021-2026)
Figure 51. China Virus-like Particles (VLPs) Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 52. Japan Virus-like Particles (VLPs) Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 53. South Korea Virus-like Particles (VLPs) Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 54. Southeast Asia Virus-like Particles (VLPs) Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 55. India Virus-like Particles (VLPs) Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 56. Australia Virus-like Particles (VLPs) Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 57. China Taiwan Virus-like Particles (VLPs) Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 58. Europe Virus-like Particles (VLPs) Vaccine Sales Market Share by Country in 2026
Figure 59. Europe Virus-like Particles (VLPs) Vaccine Revenue Market Share by Country (2021-2026)
Figure 60. Europe Virus-like Particles (VLPs) Vaccine Sales Market Share by Type (2021-2026)
Figure 61. Europe Virus-like Particles (VLPs) Vaccine Sales Market Share by Application (2021-2026)
Figure 62. Germany Virus-like Particles (VLPs) Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 63. France Virus-like Particles (VLPs) Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 64. UK Virus-like Particles (VLPs) Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 65. Italy Virus-like Particles (VLPs) Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 66. Russia Virus-like Particles (VLPs) Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 67. Middle East & Africa Virus-like Particles (VLPs) Vaccine Sales Market Share by Country (2021-2026)
Figure 68. Middle East & Africa Virus-like Particles (VLPs) Vaccine Sales Market Share by Type (2021-2026)
Figure 69. Middle East & Africa Virus-like Particles (VLPs) Vaccine Sales Market Share by Application (2021-2026)
Figure 70. Egypt Virus-like Particles (VLPs) Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 71. South Africa Virus-like Particles (VLPs) Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 72. Israel Virus-like Particles (VLPs) Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 73. Turkey Virus-like Particles (VLPs) Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 74. GCC Countries Virus-like Particles (VLPs) Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 75. Manufacturing Cost Structure Analysis of Virus-like Particles (VLPs) Vaccine in 2026
Figure 76. Manufacturing Process Analysis of Virus-like Particles (VLPs) Vaccine
Figure 77. Industry Chain Structure of Virus-like Particles (VLPs) Vaccine
Figure 78. Channels of Distribution
Figure 79. Global Virus-like Particles (VLPs) Vaccine Sales Market Forecast by Region (2027-2032)
Figure 80. Global Virus-like Particles (VLPs) Vaccine Revenue Market Share Forecast by Region (2027-2032)
Figure 81. Global Virus-like Particles (VLPs) Vaccine Sales Market Share Forecast by Type (2027-2032)
Figure 82. Global Virus-like Particles (VLPs) Vaccine Revenue Market Share Forecast by Type (2027-2032)
Figure 83. Global Virus-like Particles (VLPs) Vaccine Sales Market Share Forecast by Application (2027-2032)
Figure 84. Global Virus-like Particles (VLPs) Vaccine Revenue Market Share Forecast by Application (2027-2032)
More Publications
Global Artificial Upper Limb Joints Market Growth 2023-2029
US$ 3,660.00
March 2023
107 pages
Global Viral RNA Extraction Kit Market Growth 2023-2029
US$ 3,660.00
February 2023
122 pages
Global Compact Anesthesia Machine Market Growth 2023-2029
US$ 3,660.00
February 2023
106 pages
Global Monoclonal Antibody ADC Drugs Market Growth 2023-2029
US$ 3,660.00
February 2023
95 pages
